Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics

Published by: Decision Resources

Published: Mar. 30, 2009 - 25 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Inherent Challenges in Researching Proteins

Proving the Value of Proteomics

Understanding the Proteomics Approach

Sample Preparation

Separation and Capture, Analysis and Identifi cation

Planning Ahead for Clinical Validation

Recent Perspectives on Proteomic Technologies

Two-Dimensional Gel Electrophoresis

Mass Spectrometry

Bioinformatics Tools

Biopharma Players in the Protein Research Arena

Caprion Proteomics

NextGen Sciences

Power3 Medical Products

Notable Initiatives in Proteomics

Clinical Proteomic Technologies for Cancer

Spectrum Expert Commentary

Revitalizing Personalized Medicine Through Proteomics

Improvements in Proteomics

Protein Assay Platforms

Spectrum Expert Commentary (cont.)

Assay Availability

At a Major Turning Point

About the Author

Human Plasma Proteome Project

Outlook

Overcoming Key Challenges

Building Capacity Through Collaboration

Tables

1. Select Diagnostic Tests Based on Protein Biomarkers

2. Advantages and Disadvantages of 2DGE and MS Technologies

3. Select Protein Sequencing Databases

4. Select Proteomics Companies of Interest

5. Participants in the Clinical Proteomic Technologies for Cancer Initiative

6. Pharmaceutical and Diagnostics Company Sponsors of the Human Plasma Proteome Project

Figures

1. FDA Approval of NMEs Compared with R&D Spending, 2000-2008

2. Sensitivities and Specifi cities of Select FDA-Approved Protein Biomarkers

3. Proteomics Research Process

4. Comparison of Protein Sample Sources

5. Number of Alliances Involving Proteomics, 2001-2008

Expert Commentary

Revitalizing Personalized Medicine Through Proteomics.

M. Walid Qoronfl eh, Ph.D., M.B.A.,

Vice President of Business Development at NextGen Sciences

Abstract

• Partnering in proteomics is slowing despite the potential of the associated technologies to revolutionize drug discovery, diagnostics development, and disease management. What problems are inherent in protein biomarker research? What solutions have been developed to help overcome the obstacles?
• Navigating the proteomics research process of preparation, separation, identifi cation, and validation is complex. Which step is most critical upstream to improve results downstream?
• Proteomics technologies give rise to a select set of protein biomarkers. What are the differences between biomarkers for drug discovery and those for diagnostics development?

• Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
• Proteomics research process: Innovative methods of sample preparation, separation and capture, identifi cation and analysis, and clinical validation.
• Companies with valuable insight into protein biomarker discovery: 20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford GlycoSciences.
• Outlook: Proteomics is approaching the long-awaited recognition that it has the potential to deserve. Novel tools now in use will improve greatly owing to collaborative initiatives that will stimulate innovation in protein research processes.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.